Author(s): Merwat SN, Vierling JM
Abstract Share this page
Abstract Hepatitis C virus-Human immunodeficiency virus (HCV-HIV) coinfections are identified in up to 30\% of patients infected with HIV and in 8\% of patients infected with HCV. Now that progression of HIV and deaths due to AIDS can be prevented by highly active antiretroviral therapy (HAART), it is clear that HCV coinfection is associated with accelerated progression to cirrhosis and increased liver-related morbidity and mortality. Antiviral therapy with pegylated interferon and ribavirin for HCV in HCV-HIV coinfected patients is less successful than in patients with HCV monoinfection, and HAART can cause drug-induced liver injury. Multiple barriers limit the number of HCV-HIV coinfected patients who receive antiviral therapy for HCV, and the role of orthotopic liver transplantation (OLT) in HIV monoinfected and HCV-HIV coinfected patients remains controversial. Clinical trials of HCV-specific protease or polymerase inhibitors combined with pegylated interferon and ribavirin are needed urgently in coinfected patients, both before and after OLT. Copyright © 2011 Elsevier Inc. All rights reserved.
This article was published in Clin Liver Dis
and referenced in Journal of Clinical Toxicology